US Study Links 14 Pregnancy Drugs to 1.47x Higher Autism Risk
Updated
Updated · Futura · May 23
US Study Links 14 Pregnancy Drugs to 1.47x Higher Autism Risk
1 articles · Updated · Futura · May 23
A review of births from 2014 to 2023 found children exposed in utero to sterol biosynthesis-inhibiting medications had a 1.47-fold higher autism diagnosis risk, rising to 2.33-fold when mothers took four or more.
Fourteen common drugs—including fluoxetine, sertraline, bupropion, atorvastatin and propranolol—were grouped by their shared effect on cholesterol production, a pathway the fetal brain depends on from about 19 to 20 weeks' gestation.
Epic Cosmos records from 1,880 hospitals and 42,400 clinics covered roughly one-third of US births; among 234,000 children diagnosed with autism, 15% had prenatal SBIM exposure.
Prenatal prescribing of these drugs climbed from 4.3% of pregnancies in 2014 to 16.8% in 2023, underscoring the potential public-health reach of medications that generate more than 400 million US prescriptions a year.
The authors said the study shows correlation, not causation, because maternal depression, anxiety and hypertension may also affect neurodevelopment, and they warned patients not to stop medication without medical supervision.
Are common antidepressants and statins secretly elevating autism risk in unborn babies?
The FDA eased statin warnings for pregnancy. Does this massive study demand an urgent reversal to protect newborns?
Prenatal Exposure to Sterol Biosynthesis-Inhibiting Medications Raises Autism Risk: 2026 Study Findings and Clinical Implications
Overview
A major study published in April 2026 found that when pregnant individuals take sterol biosynthesis-inhibiting medications (SBIMs), which interfere with cholesterol synthesis, their children have a higher risk of developing autism spectrum disorder (ASD). The research shows that disrupting cholesterol and sterol pathways during key stages of fetal development can lead to neurodevelopmental differences seen in ASD. Children with genetic risks affecting sterol metabolism may be especially vulnerable. These findings highlight the importance of careful medication use during pregnancy and the need for personalized risk assessment to protect healthy brain development.